药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
Enzymatic metabolism, 277–278 278
Enzyme-linked immunosorbent assay 0
(ELISA), 162–164, 163f 163
activation energy, 97–99, 98f 98
allosteric inhibitors, 103f, 104 104
classes of, 95–96, 96f 96
cofactors/coenzymes, 99, 101f 101
competitive inhibitors, 101–103, 103f 103
irreversible inhibitors, 103f, 104–105 105
redox active compounds, 99–101, 102f 102
European Medicines Agency (EMA), 73–74 74
Fatty acid synthase, 96 96
Flavin adenine dinucleotide (FAD), 99–101,102f, 273–274, 274f 274
Flavin monooxygenase (FMO) family,273–274 274
Fluorescence-based assay systems,164–165, 164f 164
Fluorescence polarization (FP) 0
antibody technology, 167, 167f 167
DNA/protein interactions, 168, 168f 168
polarized irradiation, 166–167, 167f 167
polarized vs. depolarized emission,165–166, 166f 166
protein/protein interactions, 168, 168f 168
Fluorescence resonance energy transfer (FRET) biochemical process, 171–172 172
cell surface protein, 169–170, 170f 170
cyan fluorescent protein (CFP),170–171 171
donor/acceptor pair, 168 168
GPCR activity, 170–171 171